Plastic changes in glutamatergic synapses that lead to endurance of drug craving and addiction are poorly understood. We examined the turnover and trafficking of NMDA receptors and found that chronic exposure to the psychostimulant amphetamine (AMPH) induced selective downregulation of NMDA receptor NR2B subunits in the confined surface membrane pool of rat striatal neurons at synaptic sites. This downregulation was a long-lived event and was a result of the destabilization of surface-expressed NR2B caused by accelerated ubiquitination and degradation of crucial NR2B-anchoring proteins by the ubiquitin-proteasome system. The biochemical loss of synaptic NR2B further translated to the modulation of synaptic plasticity in the form of long-term depression at cortico-accumbal glutamatergic synapses. Behaviorally, genetic disruption of NR2B induced and restoration of NR2B loss prevented behavioral sensitization to AMPH. Our data identify NR2B as an important regulator in the remodeling of excitatory synapses and persistent psychomotor plasticity in response to AMPH.
Plastic changes in glutamatergic synapses that lead to endurance of drug craving and addiction are poorly understood. We examined the turnover and trafficking of NMDA receptors and found that chronic exposure to the psychostimulant amphetamine (AMPH) induced selective downregulation of NMDA receptor NR2B subunits in the confined surface membrane pool of rat striatal neurons at synaptic sites. This downregulation was a long-lived event and was a result of the destabilization of surface-expressed NR2B caused by accelerated ubiquitination and degradation of crucial NR2B-anchoring proteins by the ubiquitin-proteasome system. The biochemical loss of synaptic NR2B further translated to the modulation of synaptic plasticity in the form of long-term depression at cortico-accumbal glutamatergic synapses. Behaviorally, genetic disruption of NR2B induced and restoration of NR2B loss prevented behavioral sensitization to AMPH. Our data identify NR2B as an important regulator in the remodeling of excitatory synapses and persistent psychomotor plasticity in response to AMPH.
Drug addiction is a persistent mental disorder that is characterized by compulsive drug craving, seeking and ingestion in spite of severe adverse consequences. The potential brain mechanisms that underlie addiction remain elusive. Experimental animal models that mimic core features of addiction in humans have proven to be valuable for clarifying these underlying mechanisms. One animal model for experience-and drug-dependent behavioral plasticity is the progressive and enduring augmentation of psychomotor responses to repeated psychostimulant exposure, which is known as behavioral sensitization 1 . This model corresponds to the intensification of drug craving in human addicts and is readily elicited by many drugs, including the dopamine psychostimulants cocaine and AMPH.
Persistent molecular adaptations in specific neural circuits in response to repeated drug exposure are thought to lead to addiction 2, 3 . A major neural circuit in which adaptive responses are believed to occur is the mesolimbic system, a dopaminergic projection from the ventral tegmental area to the ventral striatum/nucleus accumbens (NAc). A great deal of initial work has focused on this system for defining preand postsynaptic plastic changes, establishing that altered dopaminergic transmission contributes to drug-related psychomotor plasticity 1 .
Glutamatergic inputs to the NAc are also critical for synaptic and behavioral plasticity 1, 4 . As it is a major basal ganglia structure that is abundantly innervated with glutamatergic afferents from various cortical and subcortical areas, the NAc shows robust and long-lasting changes in excitatory transmission following repeated psychostimulant administration 5, 6 , which are important for behavioral plasticity 1, 6 . In parallel with enriched glutamate afferents, ionotropic glutamate NMDA receptors (NMDARs) are densely expressed in striatal medium spiny neurons [7] [8] [9] [10] . These receptors become functional on heteromultimer assembly of the obligatory NR1 and the modulatory NR2 subunit. Among all of the modulatory subunits (A-D), NR2B is distinctly enriched in the striatum. Functionally, NR2B has been implicated in many forms of synaptic plasticity related to the physiology of striatal neurons and the pathogenesis of various neurological disorders 11 . However, whether and how NR2B adapts to AMPH remains poorly understood.
We conducted a complete set of in vivo experiments to evaluate the role of NR2B in AMPH-dependent synaptic and behavioral plasticity. We found that chronic AMPH exposure destabilized surface-expressed NR2B in the postsynaptic density (PSD) of striatal neurons. This destabilization constitutes an enduring molecular adaptation of excitatory synapses to AMPH, leading to the concurrent development of behavioral plasticity.
RESULTS

Reduction of NR2B: generality and specificity
To link behavior to NMDAR expression following chronic noncontingent AMPH exposure, we subjected rats to an AMPH sensitization regimen (intraperitoneal injection of 4 mg per kg of body weight daily for 7 consecutive days). At 14 d after the final AMPH injection, the rats were assessed for behavioral and genomic changes. We observed a robust behavioral sensitization to a challenge dose of AMPH (1.25 mg per kg, intraperitoneal) in rats pretreated with AMPH ( Fig. 1a) .
Concurrently, the amount of NR2B protein in total striatal protein homogenates was reduced in AMPH-treated rats relative to salinetreated rats (Fig. 1b) . This reduction was not confined to either the dorsal (caudate putamen, CPu) or ventral (NAc) striatum, as both structures showed comparable reductions of NR2B ( Fig. 1c-e ). To determine the type of striatal output neurons that had reduced NR2B, we conducted in situ hybridization and immunohistochemistry on the same rat brain sections ( Supplementary Fig. 1 online) . The number of neurons containing preproenkephalin (PPE) or preprodynorphin (PPD) mRNA in the NAc remained unchanged 14 d after the final AMPH. Of the neurons containing PPE mRNA, the number of cells that were immunoreactive to NR2B was reduced in AMPH-treated rats compared with saline-treated rats. A lesser reduction of NR2B occurred in neurons containing PPD mRNA. Thus, AMPH downregulates NR2B in dynorphin-containing and, to a greater extent, enkephalincontaining neurons.
We also screened other NMDAR subunits for their responses to AMPH. In normal rodents, NR1 and NR2A are expressed at moderateto-high levels in the striatum 12 . NR3A and NR3B proteins are expressed at relatively low levels 13, 14 , whereas NR2C and NR2D proteins are barely present 15 . The total levels of striatal NR1, NR2A, NR3A and NR3B proteins were not altered in response to chronic AMPH ( Supplementary Fig. 1 ), indicating that these subunits are insensitive to AMPH. Similarly, AMPH administration did not alter the expression of the presynaptic proteins, including a presynaptic plasma membrane protein (syntaxin) and two synaptic vesicle membrane proteins (synaptophysin and synapsin) ( Supplementary Fig. 1 ). AMPH also did not affect the expression of postsynaptic proteins, including a dendritic marker (microtubule-associated protein 2, MAP2), a kinase-and AMPA receptor-associated scaffold protein (A-kinase anchoring protein, AKAP), and PSD-93/chapsyn-110 (a PSD-95 homolog of the membrane-associated guanylate kinase family) ( Supplementary Fig. 1 ). Of these, only PSD-95 expression was decreased in AMPH-treated rats ( Supplementary Fig. 1 ), similar to what has been observed in the mouse striatum after repeated cocaine administration 16 . These data indicate that AMPH selectively modulates NR2B expression at excitatory synapses.
Reduction of NR2B: spatial and temporal characteristics
Other forebrain and midbrain structures, including the prefrontal cortex, hippocampus, amygdala and ventral tegmental area, express NR2B and have been implicated in stimulant action 17 . However, chronic AMPH administration did not alter NR2B expression in these regions ( Supplementary Fig. 2 online) . Thus, AMPH-induced downregulation of NR2B appears to be selective to the striatum.
AMPH-induced behavioral plasticity is characterized by its longlived nature. Altered receptor expression, if it lasted long enough, could serve as a critical molecular mechanism for the nearly permanent behavioral modification 3 . We thus explored the candidacy of NR2B downregulation as a potential mechanism. We observed a long-lasting decrease in NR2B ( Fig. 1f,g) . No change in NR1 and NR2A was observed at all time points. Behavioral responses to a challenge dose of AMPH (1.25 mg per kg, intraperitoneal) were augmented at 28 and 60 d in AMPH-treated, but not saline-treated, rats. In naive rats, acute injection of AMPH (4 mg per kg, intraperitoneal) did not alter striatal NR1, NR2A or NR2B levels 1 d after injection ( Supplementary Fig. 2) . These results reveal an enduring NR2B downregulation that closely correlates with persistent behavioral plasticity.
NR2B reduction in a specific subcellular compartment
The subcellular localization of NMDARs determines the receptor properties and is subject to modulation by changing synaptic inputs 12, 18 . After finding an overall reduction of NR2B in total protein homogenates, we next investigated the response of NR2B to AMPH in different subcellular domains. We carried out biochemical fractionation to isolate proteins from distinct subcellular compartments 12 . The membrane-bound proteins were isolated mainly from the synaptosomal membrane (LP1) and the intracellular membrane fractions. The latter included membrane from two sources: the intracellular light membrane fraction (P3), which contains organelles such as the endoplasmic reticulum/Golgi apparatus for the synthesis and assembly of NMDARs 19 , and the intracellular vesicular membrane fraction (LP2), which contains organelles such as vesicles for the trafficking of NMDARs (Fig. 2a ). The effectiveness of fractionation was validated by confirming the unique expression patterns of protein markers of distinctive compartments (Fig. 2b) . The synaptic vesicular membrane protein synaptophysin was present in the LP2 at a high level. Calnexin, a Ca 2+ -binding protein that is known to interact with glycoproteins in the endoplasmic reticulum 20 , was detected in the P3 fraction. a-actinin had a wider subcellular distribution as a result of its expression in both membrane and cytosolic fractions. NR2B and NR1 are membrane proteins that are bound to either surface or intracellular membranes 12 . Both proteins were present in the P2 (crude synaptosomal membranes) and LP1 fractions at high levels, in the P3 and LP2 fractions at low levels, and were undetectable in the S3 (cytosolic fraction) and LS2 (cytosolic synaptosomal fraction). Notably, AMPH reduced NR2B levels in the homogenate, P2 and LP1 fractions after 14 d of withdrawal ( Fig. 2b,c) . However, AMPH slightly increased NR2B in the P3 and LP2 (although P 4 0.05). As a result, the ratio of NR2B in the LP1 to NR2B in the P3/LP2 fractions was reduced (0.58 ± 0.09-fold of saline, P o 0.05). Meanwhile, AMPH did not alter NR1, a-actinin, synaptophysin or calnexin in any fraction (Fig. 2b,c) . A further attempt was made to isolate the PSD from excitatory synapses in striatal tissue. NR2B and NR1 proteins were abundant in the isolated PSD ( Fig. 2d) 21 . The purity of the PSD was confirmed by the lack of PKCe, a PKC isozyme that is present only in the presynaptic compartment ( Fig. 2d ). AMPH reduced NR2B expression, but not that of NR1 or NR2A, in the PSD ( Fig. 2e ). These results demonstrate selective NR2B downregulation in a specific subcellular compartment (synaptosomal membranes).
To substantiate and confirm this compartment-specific effect, we employed two other biochemical techniques to isolate native receptors from surface and intracellular pools in intact neurons 22, 23 . First, we treated striatal tissue with membrane-impermeable bis(sulfosuccinimidyl)suberate (BS 3 ). This reagent selectively crosslinks surface membrane-bound receptors to form high-molecular weight aggregates that can be readily separated from unlinked intracellular receptors by gel electrophoresis. Second, we treated striatal tissue with the protease chymotrypsin to cleave the extracellular N-terminal domains of surface receptors. This generates receptor fragments with molecular weights that are lower than those of intact intracellular receptors. In BS 3 -treated tissue, NR1 and NR2B had a high-molecular weight band (surface subunits) and a monomeric molecular weight band (intracellular subunits), as compared with a single monomeric molecular weight band (surface and intracellular subunits) in noncross-linked tissue (Fig. 3a) . Proteolysis with chymotrypsin revealed a smaller molecular-weight band (surface) and a monomeric molecularweight band (intracellular), which was detected with an antibody to the intracellular C terminus. The selectivity of BS 3 and chymotrypsin was confirmed by their lack of effect on a-actinin, an intracellular protein ( Fig. 3a) . Moreover, treatment of striatal homogenates with either BS 3 or chymotrypsin completely eliminated the monomeric NR1 and NR2B bands (data not shown). Both assays yielded nearly identical estimates of the percentages of NR1 and NR2B in the surface (Fig. 3b ) and the intracellular pools (approximately 20-40%).
We next examined the effects of AMPH on NR2B in the surface and intracellular pools. After 14 d of withdrawal, we observed a robust decrease in the amount of NR2B in the surface pool of AMPH-treated rats in BS 3 cross-linking experiments (Fig. 3c ). This was accompanied by a slight increase in the amount of NR2B in the intracellular pool (although P 4 0.05). Mostly as a result of the decrease in surface NR2B, the total protein level (surface and intracellular; Fig. 3c ) and the surface:intracellular ratio of NR2B (0.56 ± 0.1-fold of saline, P o 0.05) were reduced. Similar results were observed in NR2B assays with chymotrypsin in the intracellular pool ( Fig. 3d) . No changes were seen in the levels of NR1 or a-actinin ( Fig. 3c,d) . These results demonstrate a selective decrease in NR2B in the confined surface pool.
AMPH increases ubiquitination of synaptic proteins
The regulated degradation of proteins by the ubiquitin proteasome pathway appears to be an important modulator of synaptic plasticity 24, 25 . We therefore investigated whether chronic AMPH regulates ubiquitin conjugation of striatal synaptosomal proteins after a 14-day withdrawal. Ubiquitin conjugates were abundant in saline-treated rats and increased in AMPH-treated rats (126.1 ± 0.7% of saline, P o 0.05; Fig. 4a ). To directly examine de novo ubiquitin conjugation, we conducted ubiquitin conjugation assays. Strong ATP-dependent ubiquitin conjugation was observed in both cytosol and synaptosomes of striatal neurons from normal rats ( Fig. 4b) , indicating that all of the necessary elements for an effective ubiquitin incorporation machinery were present in these biochemically enriched subcellular fractions. In addition, AMPH enhanced ubiquitin conjugation in synaptosomes and the PSD but not in the cytosol ( Fig. 4c and Supplementary Fig. 3 online). These results provide direct evidence for the ability of AMPH to regulate ubiquitin conjugation at synaptic sites and to enhance the susceptibility of postsynaptic proteins to proteasomemediated degradation. We next sought to identify specific substrates for ubiquitin conjugation at excitatory synapses. We first purified polyubiquitinated proteins from striatal synaptosomes in pull-down assays with a glutathione-S-transferase (GST) fusion protein, high-affinity polyubiquitinbinding proteasome subunit S5a (GST-S5a). Abundant ubiquitinated proteins were readily precipitated by GST-S5a but not by GST alone (Fig. 5a) . The de-ubiquitinating enzymes isopeptidase-T and UCH-L3 abolished the precipitation of ubiquitinated proteins (Fig. 5a) , confirming that the purification was ubiquitin mediated. We then identified specific polyubiquitination substrates in GST-S5a precipitates using a panel of antibodies in subsequent immunoblots. Three key multivalent postsynaptic scaffolds, Shank/ProSAP, guanylate kinaseassociated protein (GKAP) and AKAP, were present as high-molecular weight ubiquitinated species (Fig. 5b) . In contrast, other PSD proteins that we surveyed, including PSD-95, NR1 and NR2B, were not detected. Thus, similar to cultured cortical neurons 24 , polyubiquitination normally occurs in a selective subset of scaffold proteins in striatal neurons in vivo.
To directly test whether AMPH affects the ubiquitination of Shank, GKAP and/or AKAP, we carried out GST-S5a pull-down assays with striatal synaptosomes from saline-or AMPH-treated rats after 14 d of withdrawal. We observed a significant increase in the ubiquitination of Shank and GKAP (P o 0.05), but not AKAP (P 4 0.05), in AMPHtreated rats (Fig. 5c,d) , identifying Shank and GKAP as two substrates that are sensitive to AMPH. It is thought that the ubiquitination and degradation of these two scaffold proteins may affect the stability of the proteins that require Shank and/or GKAP to anchor them to the PSD. Shank and GKAP are known to anchor PSD-95 and thus PSD-95linked NR2B. Both PSD-95 and NR2B had a parallel reduction in their abundance after AMPH administration. Thus, ubiquitination of crucial anchoring proteins in the PSD could affect the stability of PSD-95 and NR2B, even though they are not direct ubiquitin targets. Indeed, this idea was supported by further pharmacological studies. Treatment of striatal slices with either of two structurally distinct cell-permeable proteasome inhibitors, MG132 (5 mM, 3 h) or lactacystin (2 mM, 3 h), markedly rescued the reduction of synaptosomal Shank and GKAP in AMPH-treated rats ( Fig. 5e and Supplementary Fig. 4 online). This rescue was mediated through the selective suppression of proteasomemediated degradation, as inhibition of the lysosome with leupeptin (50 mg ml -1 , 3 h) had no effect (data not shown). Notably, the reduction of NR2B and PSD-95 was reversed simultaneously by MG132 and lactacystin in AMPH-treated rats ( Fig. 5e and Supplementary Fig. 4 ). Thus, Shank and GKAP are master regulators that stabilize PSD-95 and NR2B in the PSD. Their accelerated removal destabilizes PSD-95 and NR2B, leading to the concurrent loss of these protein cohorts.
Destabilization of NR2B affects synaptic plasticity
We carried out whole-cell voltage-clamp recordings of synaptically evoked NMDAR-mediated excitatory postsynaptic currents (EPSCs) in NAc slices to explore whether the biochemical destabilization of NR2B can translate to the modulation of NR2B-NMDARs. The relative contribution of NR2B to EPSCs was determined by measuring the sensitivity of EPSCs to ifenprodil, an NR2B-selective inhibitor. Ifenprodil-sensitive EPSCs were substantially reduced in AMPHtreated rats after a 14-d withdrawal period (30.6 ± 6.4% of saline, P o 0.05; Fig. 6a ). Consistent with this, the decay constant for NMDA EPSCs was smaller (58.7 ± 3.5 ms for saline, 39.3 ± 3.3 ms for AMPH, P o 0.05). Thus, the loss of surface NR2B impairs ifenprodil-sensitive NR2B-NMDAR-mediated currents. We examined two forms of synaptic plasticity at cortico-accumbal glutamatergic synapses, paired-pulse facilitation (PPF) and longterm depression (LTD), in NAc slices to determine the modulation of synaptic plasticity. PPF is a sensitive measure of the probability of transmitter release and a common form of short-term presynaptic plasticity. AMPH had no effect on PPF after 14 d of withdrawal ( Fig. 6b ), suggesting a lack of gross change in presynaptic function. We then assessed an NMDAR-dependent form of synaptic plasticity (LTD). We found that LTD was reduced in AMPH-treated rats compared with saline-treated rats (Fig. 6c,d) . To determine whether the loss of NR2B contributes to this reduction of LTD, we treated NAc slices from AMPH-treated rats with the proteasome inhibitor MG132, which has previously been shown to reverse the loss of NR2B (Fig. 5e ). We then compared the LTD recorded in these slices with the LTD recorded in slices that were treated with vehicle control (DMSO). We found that MG132 (5 mM, 3 h), but not DMSO, markedly restored LTD (Fig. 6e,f) . MG132 did not alter normal LTD in saline-treated rats ( Supplementary Fig. 5 online) . Thus, NR2B loss appears to contribute to the impairment of cortico-accumbal LTD in response to AMPH.
Role of NR2B in regulating behavioral sensitivity to AMPH
We used both pharmacological and genetic approaches to determine whether the biochemical and electrophysiological remodeling of NR2B-NMDARs leads to the regulation of behavioral sensitivity to acute and chronic AMPH. The systemically active NR2B antagonist RO25-6981 (half maximal inhibitory concentration of 9 nM for NR1/ NR2B and 52 mM for NR1/NR2A) 26 did not alter spontaneous motor activity (Fig. 7a) , but it augmented the locomotor response to acute injection of both AMPH (1.25 mg per kg, intraperitoneal; Fig. 7b ) or the D1 receptor agonist SKF81297 (0.5 mg per kg, intraperitoneal; Supplementary Fig. 6 online) at 0.4 mg per kg in naive rats. Another NR2B antagonist, ifenprodil (1-2 mg per kg), also augmented motor responses to AMPH ( Supplementary Fig. 6 ). To determine whether the effect of systemic RO25-6981 occurs locally in the striatum, we carried out a microinjection study. Injections of this agent into the NAc produced the same effect as that seen after systemic injections (Fig. 7c,d) . These data indicate that NR2B-NMDARs inhibit behavioral sensitivity to acute AMPH. We next explored the role of NR2B in behavioral sensitization (Fig. 7e) . At 14 d after withdrawal, challenge injections of saline and AMPH (1.25 or 2 mg per kg) induced an augmented behavioral response in AMPHpretreated rats compared with salinepretreated rats ( Fig. 7f and Supplementary  Fig. 6 ). In contrast, challenge treatments with RO25-6981 (0.4 mg per kg) and AMPH (1.25 or 2 mg per kg) induced nearly identical locomotor activities in saline-and AMPH-treated rats ( Fig. 7g and Supplementary Fig. 6 ). Similar results were seen in our experiments with ifenprodil ( Supplementary  Fig. 6 ). These data demonstrate that antagonism of NR2B induces sensitization-like behavioral responses to challenge injections of AMPH in saline-pretreated rats, which are comparable to those seen in AMPHpretreated rats. It is therefore possible that the downregulation of NR2B after chronic AMPH constitutes a critical molecular step leading to behavioral sensitization.
The role of NR2B was then evaluated in vivo using a region-specific genetic approach with small interfering RNAs (siR-NAs). We targeted the NAc because it is a central site that is critical for the expression of behavioral sensitization 1 and is also a key limbic structure for molecular studies linking glutamate receptors and scaffolds to sensitized behavior 5, 16, 27 . Intra-accumbal infusions of NR2B siRNAs at a higher dose (5, but not 0.5, mg per side, once daily for 3 d, 1 d after final injection) reduced the percentage of NR2B present in total protein (Fig. 8a,b ) and in the LP1 fraction (data not shown) in the injected site. The reduction was only partial or insignificant (P 4 0.05) 3 or 5 d after the final siRNA treatment, respectively. No effect of NR2B siRNAs was seen on total NR2A and NR1 proteins. In addition, in NR2B siRNAand control siRNA-treated rats, there was no difference in the number of apoptotic cells as detected by fragment-end labeling and the number of pyknotic cells in striatal slices. These data demonstrate the selective, reversible and nontoxic knockdown of NR2B.
We next examined whether NR2B siRNAs affect behavioral responses to acute AMPH in naive rats. Intra-accumbal injection of NR2B siRNAs augmented horizontal locomotor responses to AMPH in a dose-dependent manner (Fig. 8c) . However, injection of NR2B siRNAs into the dorsolateral striatum had little effect on locomotor activity induced by AMPH, even though the siRNA still reduced the level of NR2B at the injected site ( Supplementary Fig. 7 online) . We then assessed the effect of NR2B siRNAs in our chronic model ( Fig. 8d) . At day 14 (1 d after final siRNA injection), a challenge AMPH injection (1.25 mg per kg) induced the typical behavioral sensitization that we observed in rats pretreated with AMPH followed by intra-accumbal injections of control siRNAs. However, in rats treated with NR2B siRNAs, AMPH produced no further behavioral sensitization in AMPH-pretreated rats compared to saline-pretreated rats. At day 20 (7 d after the final siRNA injection), a time at which the knockdown of NR2B by siRNAs recovered to normal levels, AMPH resumed its ability to elicit greater behavioral responses in AMPH-pretreated rats than in saline-pretreated rats. These results complement those of our experiments with RO25-6981 and support the requirement of NR2B downregulation for the full expression of motor sensitization.
Further efforts were made to evaluate the importance of NR2B. At 14 d, after 7 daily injections of AMPH, intra-accumbal injection of the proteasome inhibitor MG132 (0.2 mg) reversed the loss of NR2B in the injected NAc and reduced the sensitized motor response to a challenge dose of AMPH, whereas DMSO had no effect (Fig. 8e) . Intra-accumbal injection of lactacystin (0.2 mg) produced similar results (Fig. 8f) . Neither MG132 nor lactacystin affected behavioral responses to acute AMPH injection ( Supplementary Fig. 8 online) . In another approach, bilateral intra-accumbal injections of lactacystin (0.2 mg) were given 5 min before each daily saline or AMPH injection ( Supplementary Fig. 9 online). After 7 d of withdrawal, lactacystin reduced behavioral sensitization to a challenge dose of AMPH ( Supplementary Fig. 9 ) and the accumbal loss of NR2B ( Supplementary Fig. 9 ). These data provide further support for the idea that the loss of NR2B is required for behavioral sensitization to AMPH.
DISCUSSION
Accumbal NR1 proteins remain stable after chronic cocaine exposure in most early studies [28] [29] [30] . Unlike NR1, NR2B expression was reduced after chronic AMPH administration. This reduction seems to be a general adaptation of the entire striatum (both the NAc and CPu), as is seen in the case of the NR2B-anchoring protein PSD-95 (ref. 16 ). However, in light of well-documented differences between the ventral and dorsal striatum 31 , the loss of NR2B in the two classical divisions (NAc and CPu) or in the different NAc regions (shell and core) may have distinct effects on synaptic and behavioral plasticity. At the cellular level, NR2B expression was reduced in a greater number of D2 receptor-bearing striatopallidal output neurons than D1 receptor-bearing striatonigral output neurons. This seems to imply that downregulation of NR2B-NMDARs has a greater effect on the D2 receptor-dependent striatopallidal indirect pathway than the D1 receptor-dependent striatonigral direct pathway in the basal ganglia. Future studies are needed to clarify the region-and cell type-specificity of NR2B adaptations to AMPH in terms of the expression and function of the subunit.
We found a selective loss of NR2B in the surface membrane at synaptic sites. In contrast to the surface section, NR2B in the intracellular pools involved in synthesis, assembly and secretion of proteins was insensitive to AMPH. Notably, striatal NR2B mRNAs were not altered after repeated cocaine administration 32 . Thus, it is less likely that an overall inhibition of new NR2B protein synthesis could account for the NR2B reduction. Suppressed trafficking or delivery of NR2B from the intracellular pool to the surface membrane is also unlikely, as impaired NR2B externalization of this kind should cause a redistribution phenomenon that is characterized by the removal of NR2B in the surface pool in combination with the proportional addition of Figure 8 Effects of NR2B siRNAs on behavioral responses to AMPH. (a) Locations of microinjection sites in the NAc. Control or NR2BV siRNAs were bilaterally injected into the NAc. (b) Intra-accumbal injection of NR2B siRNAs reduced the total levels of NR2B proteins in the injected side. (c) Intra-accumbal injection of NR2B siRNAs augmented behavioral responses to acute AMPH injection (1.25 mg per kg) in naive rats (n ¼ 4, 5, 4, 6, 5 and 6 from left to right). (d) Effects of intraaccumbal injection of NR2B siRNAs on behavioral responses to a challenge AMPH injection in saline-and AMPH-treated rats (n ¼ 8, 9, 14, 11, 8, 9, 12 and 10 from left to right). (e,f) MG132 and lactacystin reduced the behavioral sensitization (n ¼ 8-12 per group). Bilateral intra-accumbal injections of DMSO, MG132 (0.2 mg ml -1 ) or lactacystin (0.2 mg ml -1 ) were made 3 h before a challenge saline or AMPH injection at 14 d after withdrawal. NR2B levels were tested in the injected sites (inset) 3 h after intra-accumbal injections of DMSO or MG132 in rats pretreated with chronic saline or AMPH after a 14-d withdrawal period. In naive rats, siRNAs were injected bilaterally into the NAc at 0.5 or 5 mg per 0. NR2B in the intracellular pool, with total NR2B protein remaining unchanged 12, 23 . The fact that the NR2B downregulation occurred selectively in the surface pool implies a scenario in which the removal of existing NR2B from the surface pool is accelerated, followed by enhanced degradation of the protein 12, 24, 33 . Our evidence supports this scenario (see below). Increasing evidence supports the idea that ubiquitination and degradation of synaptic proteins serve as an underlying mechanism for the enduring modification of protein expression and function at excitatory synapses 25, 34 . To date, a subset of synaptic scaffolds, including Shank, GKAP and AKAP, have been found to be polyubiquitinated in hippocampal and cortical neurons 24, 35 . The data regarding PSD-95 and NR1 ubiquitination are less consistent 24, [35] [36] [37] .
Here we screened a number of synaptic proteins for ubiquitination in striatal neurons in vivo. We found that Shank, GKAP and AKAP, but not NR1, NR2B or PSD-95, were among the direct targets of ubiquitin. More importantly, two out of these three scaffold proteins (Shank and GKAP) showed increased ubiquitination in response to AMPH. AKAP is a scaffold protein that links PSD-95 to various kinases, whereas GKAP, a much more abundant multi-domain scaffold protein, links PSD-95 to Shank, which in turn anchors the complex to the predominant filamentous actin (F-actin) cytoskeleton via actin-interacting proteins 38 . Thus, the degradation of the two master PSD-95-anchoring proteins (Shank and GKAP) can impair the stability of PSD-95. Because it has been well established that PSD-95 inhibits NR2B internalization and stabilizes surface NR2B at synaptic sites 39, 40 , impairing PSD-95 may cause destabilization of NR2B, despite the fact that neither PSD-95 nor NR2B are direct substrates of ubiquitination. This model is supported by our pharmacological experiments, in which the proteasome inhibitors, which blocked the Shank and GKAP degradation, reversed the loss of PSD-95 and NR2B in AMPH-treated rats.
Our results may reveal a metaplastic basis for AMPH-associated learning and memory 3, 41 . Striatal neurons are among those that readily express LTD 27, 42 , a cellular model of synaptic plasticity for learning and memory. This homosynaptic plasticity is NMDAR dependent 42 and is subject to modification by addictive drugs. For example, a challenge injection of cocaine reduces LTD in the NAc in mice that have been chronically treated with cocaine 5 . Enduring inhibition of LTD occurs in the NAc of rats that are trained to self-administer cocaine (contingent administration), although not in yoked rats treated with repeated noncontingent administration (experimenter administered) of cocaine 43 . Blunted LTD in the striatum is also seen after chronic exposure to other psychoactive drugs (methamphetamine, cannabinoid and ethanol) [44] [45] [46] . These data support an inhibitory modulation of LTD by these drugs, which is consistent with our findings in rats exposed to AMPH. This inhibited LTD, together with the reduced basal intrinsic excitability of postsynaptic NAc neurons and the augmented long-term potentiation (LTP) in the NAc 16 , could be among the cardinal features of abnormal synaptic plasticity derived from chronic stimulant exposure 41 . These plastic changes probably occur in a subset of excitatory synapses on spiny neurons and are critical for the expression of behavioral plasticity 5, 16 . The loss of surface NR2B at synaptic sites seems to confer an attractive metaplastic mechanism for these changes. It is possible, although it requires further experimental clarification, that the subtraction of surface NR2B contributes to the development of a relatively depressed state of spiny neurons, which permits lesser induction of LTD and greater induction of LTP in reward circuits 41 .
The AMPA receptor is another target of stimulants. Increased AMPA receptor transmission in the NAc has been shown to promote cocaine-seeking 47 and psychomotor sensitization 23, 29 , whereas other studies have found no link, or an inverse one, between AMPA receptor expression levels and these behaviors [48] [49] [50] . In either case, weakened NR2B-NMDARs with or without relatively strengthened NR2A-NMDARs can contribute to modulating AMPA receptors at defined subsets of synapses. As such, the two receptors act in concert to determine behavioral sensitivity to stimulants. Future studies need to elucidate how, when and where they interact to control synaptic and behavioral plasticity.
METHODS
Animals. Adult male Wistar rats weighing 175-200 g (Charles River) were individually housed in a controlled environment at a constant temperature of 23 1C and humidity of 50 ± 10% with food and water available ad libitum. The animal room was on a 12-h/12-h light/dark cycle. Rats were allowed 6-7 d of habituation to the animal colony. All animal use procedures were in strict accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committees of the University of Missouri Kansas City and Huazhong University of Science and Technology.
Surface receptor cross-linking assays. Surface expression of NR2B was assayed using the membrane-impermeable cross-linking reagent BS 3 , which only cross-links proteins on the surface of live cells 23 . Brains were removed following anesthesia and sliced (400 mm). The striatum was dissected and added to Eppendorf tubes containing ice-cold artificial cerebrospinal fluid (ACSF). We added 2 mM BS 3 (Pierce) and incubated the sample with gentle agitation for 30 min at 4 1C. The cross-linking reaction was terminated by quenching with 20 mM glycine (10 min, 4 1C). The tissue was then washed four times in cold ACSF (10 min each), homogenized to obtain total protein homogenate and analyzed directly by SDS-PAGE (4-12% Tris-glycine gels, Invitrogen).
Chymotrypsin assays. The striatal slices were added to Eppendorf tubes containing ice-cold ACSF. Chymotrypsin (Worthington Biochemical) was added to 1 mg ml -1 and incubated at 32 1C for 45 min. Proteolysis was stopped by three 1-min washes with cold ACSF containing 1 mM of an irreversible chymotrypsin inhibitor 4-(2-aminoethyl)benzenesulphonyl fluoride. The tissue was then homogenized to obtain total protein homogenate and analyzed directly by SDS-PAGE (4-12% Tris-glycine gels).
AMPH treatments and behavioral assessments. In all experiments involving AMPH sensitization, rats were treated with a single daily intraperitoneal injection of AMPH (D-amphetamine sulfate, 4 mg per kg) for 7 consecutive days in home cages. Age-matched rats received 7 daily intraperitoneal injections of saline (1 ml per kg of body weight) and served as controls. Before the 7-d treatment regimen, all rats were routinely injected with saline (once daily for 2 d) to accommodate them to injection procedures. Behavioral responses to a challenging dose of AMPH (1.25 mg per kg, intraperitoneal) were analyzed 14 d, or as indicated, after the last injection. Locomotion in an open field in a soundattenuated room was evaluated with an infrared photocell-based automated Opto-Varimex-Micro apparatus (Columbus Instruments) under illuminated conditions 21 . Rats were placed in an activity chamber and were habituated to the chamber environment for 2 h before each experiment. Three sensor pairs positioned in the x, y (horizontal) and z (vertical) directions were assigned to each cage and the number of infrared beam interruptions by the rats was transferred from all sensors to a computer. Information about horizontal and vertical activities was recorded at 5-min intervals before and after a dose of saline or AMPH.
Statistics. The data were evaluated using a one-or two-way ANOVA, as appropriate, followed by a Bonferroni (Dunn) comparison of groups using least squares-adjusted means. Probability levels of P o 0.05 were considered to be statistically significant. Additional methods are available in the Supplementary Methods online.
Note: Supplementary information is available on the Nature Neuroscience website.
